XML 19 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Changes in Equity - USD ($)
shares in Millions, $ in Millions
Total
Ordinary Shares [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Treasury Shares [Member]
Total Teva Shareholders' Equity [Member]
Non-controlling Interests [Member]
Beginning balance at Dec. 31, 2021 $ 11,244 $ 57 $ 27,561 $ (10,529) $ (2,683) $ (4,128) $ 10,278 $ 966
Beginning balance, shares at Dec. 31, 2021   1,209            
Net income (loss) (952)     (955)     (955) 3
Other comprehensive income (loss) (57)       (4)   (4) (53)
Issuance of Shares, value 1   1       1  
Issuance of Shares, shares   7            
Stock-based compensation expense 24   24       24  
Ending balance at Mar. 31, 2022 10,260 $ 57 27,587 (11,484) (2,687) (4,128) 9,344 916
Ending balance, shares at Mar. 31, 2022   1,216            
Beginning balance at Dec. 31, 2022 8,691 $ 57 27,688 (12,882) (2,838) (4,128) 7,897 794
Beginning balance, shares at Dec. 31, 2022   1,217            
Net income (loss) (238)     (205)     (205) (33)
Other comprehensive income (loss) 127       136   136 (9)
Issuance of Shares, shares   9            
Stock-based compensation expense 32   32       32  
Ending balance at Mar. 31, 2023 $ 8,612 $ 57 $ 27,719 $ (13,086) $ (2,701) $ (4,128) $ 7,860 $ 751
Ending balance, shares at Mar. 31, 2023   1,226